Skip to content

Free cash flow at other companies

Gilead Sciences logo
Gilead SciencesGILD
$2.43B+46.8%
Arrowhead Research logo
Arrowhead ResearchARWR
LQD
Liquidia CorporationLQDA
Alkermes logo
AlkermesALKS
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
TG Therapeutics logo
TG TherapeuticsTGTX

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s free cash flow?
Mirum Pharmaceuticals, Inc. (MIRM) reported free cash flow of -$229.43M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s free cash flow changed year-over-year?
Mirum Pharmaceuticals, Inc.'s free cash flow decreased by 11359.9% year-over-year, from -$2M to -$229.43M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s free cash flow?
Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s free cash flow has grown at a -25.5% compound annual growth rate (CAGR), from -$132.78M to $54.87M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.